PSMA-617

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
051020152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
BACKGROUND The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them… (More)
Is this relevant?
2016
2016
UNLABELLED Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
The biochemical and radiological responses to radionuclide therapy with Lu-PSMA-617 targeting prostate-specific membrane antigen… (More)
Is this relevant?
2016
2016
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe… (More)
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Dear Editor, With great interest we read the manuscript by Yadav et al. [1] according toxicity and efficacy of radio ligand… (More)
Is this relevant?
2016
2016
OBJECTIVE PSMA-617 is reported to exhibit very high binding affinity towards PSMA receptors, over-expressed on prostate cancer… (More)
Is this relevant?
2015
2015
UNLABELLED Despite many advances in the past years, the treatment of metastatic prostate cancer still remains challenging. In… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?